Clinical Trials Bristol-Myers Squibb invested $3.9 billion in 2012 to discover and develop innovative medicines to help patients prevail against serious diseases.
In the past several years, we have delivered a number of new products for patients in need, including medicines for psychiatric disorders, rheumatoid arthritis, hepatitis B, cancer, HIV/AIDS and diabetes. In addition, our pipeline
continues to expand. In all, there are more than 60 investigational compounds in 10 diseases areas, listed below. About one-third of our compounds in development are biologics.
- Alzheimer’s disease
- Heart disease
- Organ transplant rejection
- Psychiatric disorders
- Rheumatoid arthritis
In the true spirit of science, we are dedicated to educating and sharing our clinical trials information and data with patients, medical/research communities, the media, policy makers and the general public. We act on our belief that the priceless ingredient of every product is the integrity of its maker.